What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks”In the company’s words, NCT05919680 on ClinicalTrials.gov
- Tested for
- Intestinal Failure Associated Liver Disease
- Main trialPhase 2
- “This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving parenteral nutrition (PN). The study will be conducted in 2 sequential parts. Up to 36 subjects diagnosed with IFALD will be enrolled in the study, of which up to 18 subjects will be enrolled in each of the 2 parts and randomized (2:1) to receive NST-6179 (N=12/part) or matched placebo (N=6/part). Subjects in Part A will receive once…”In the company’s words, NCT05919680 on ClinicalTrials.gov
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Jun 2025 | A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD). | |
| Phase 1Completed | 27 May 2022 | Study of NST-6179 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026